

# PDA ICH Q5A R2 Essentials: Training and Practical Applications Workshop 2025

## Agenda

### Monday, 23 June

CEST Daylight Time (UTC +2:00)

09:00 – 09:05	<p><b>Welcome and Introduction</b></p> <p><b>Falk Klar PhD</b>, General Manager, Vice President Europe, <i>Parenteral Drug Association</i></p> <p><b>Alison Armstrong PhD</b> Senior Director, Global Head Scientific and Regulatory Consultancy <i>Merck KgAG</i></p>								
09:05 – 09:20	<p><b>Navigating ICH Q5A R2: From Theory to Practice</b></p> <p><b>Andy Bailey PhD</b>, CEO, <i>VirusSure GmbH</i></p>								
09:20 – 10:35	<p><b>Introduction of New Modalities and Impact of Virus Safety</b></p> <p><b>Moderator: Alison Armstrong PhD</b>, Senior Director, Global Head Scientific and Regulatory Consultancy, <i>Merck KgAG</i></p> <table border="1" data-bbox="236 969 1535 1451"> <tr> <td data-bbox="236 969 422 1111">09:20 – 09:35</td> <td data-bbox="422 969 1535 1111"> <p><b>ICH Q5AR2 Annex 6: Genetically Engineered Viral Vectors and Viral Vector-Derived Products</b></p> <ul style="list-style-type: none"> <li>• <b>Anne Stokes PhD</b>, , <i>GSK</i></li> </ul> </td> </tr> <tr> <td data-bbox="236 1111 422 1252">09:35 – 09:50</td> <td data-bbox="422 1111 1535 1252"> <p><b>Minimizing Viral Risk: New Analytical Technologies, Testing Approaches</b></p> <ul style="list-style-type: none"> <li>• <b>Marie Murphy PhD</b>, , <i>Eli Lilly &amp; Co. Ireland</i></li> </ul> </td> </tr> <tr> <td data-bbox="236 1252 422 1393">09:50 – 10:05</td> <td data-bbox="422 1252 1535 1393"> <p><b>Questions on Applications of New Modalities and Testing</b></p> <ul style="list-style-type: none"> <li>• <b>Arifa S Khan PhD</b>, Supervisory Microbiologist, DVP, OVR, CBER, <i>U.S. FDA</i></li> </ul> </td> </tr> <tr> <td data-bbox="236 1393 422 1451">10:05 – 10:35</td> <td data-bbox="422 1393 1535 1451"> <p><b>Open Discussion</b></p> </td> </tr> </table>	09:20 – 09:35	<p><b>ICH Q5AR2 Annex 6: Genetically Engineered Viral Vectors and Viral Vector-Derived Products</b></p> <ul style="list-style-type: none"> <li>• <b>Anne Stokes PhD</b>, , <i>GSK</i></li> </ul>	09:35 – 09:50	<p><b>Minimizing Viral Risk: New Analytical Technologies, Testing Approaches</b></p> <ul style="list-style-type: none"> <li>• <b>Marie Murphy PhD</b>, , <i>Eli Lilly &amp; Co. Ireland</i></li> </ul>	09:50 – 10:05	<p><b>Questions on Applications of New Modalities and Testing</b></p> <ul style="list-style-type: none"> <li>• <b>Arifa S Khan PhD</b>, Supervisory Microbiologist, DVP, OVR, CBER, <i>U.S. FDA</i></li> </ul>	10:05 – 10:35	<p><b>Open Discussion</b></p>
09:20 – 09:35	<p><b>ICH Q5AR2 Annex 6: Genetically Engineered Viral Vectors and Viral Vector-Derived Products</b></p> <ul style="list-style-type: none"> <li>• <b>Anne Stokes PhD</b>, , <i>GSK</i></li> </ul>								
09:35 – 09:50	<p><b>Minimizing Viral Risk: New Analytical Technologies, Testing Approaches</b></p> <ul style="list-style-type: none"> <li>• <b>Marie Murphy PhD</b>, , <i>Eli Lilly &amp; Co. Ireland</i></li> </ul>								
09:50 – 10:05	<p><b>Questions on Applications of New Modalities and Testing</b></p> <ul style="list-style-type: none"> <li>• <b>Arifa S Khan PhD</b>, Supervisory Microbiologist, DVP, OVR, CBER, <i>U.S. FDA</i></li> </ul>								
10:05 – 10:35	<p><b>Open Discussion</b></p>								
10:35 – 11:05	<p><b>Coffee Break</b></p>								
11:05 – 13:00	<p><b>Continuous Biomanufacturing</b></p> <p><b>Moderator: Johannes Bluemel PhD</b>, Head of Virus Safety Section, <i>Paul-Ehrlich-Institut</i></p> <table border="1" data-bbox="236 1655 1535 2089"> <tr> <td data-bbox="236 1655 422 1796">11:05 – 11:25</td> <td data-bbox="422 1655 1535 1796"> <p><b>Continuous Biomanufacturing – ICH Q5A (R2) Training Materials</b></p> <ul style="list-style-type: none"> <li>• <b>Marie Murphy PhD</b>, , <i>Eli Lilly &amp; Co. Ireland</i></li> </ul> </td> </tr> <tr> <td data-bbox="236 1796 422 1966">11:25 – 11:45</td> <td data-bbox="422 1796 1535 1966"> <p><b>Viral Inactivation in Continuous Mode: Advancing Innovation Through Engagement With Regulatory Agencies</b></p> <ul style="list-style-type: none"> <li>• <b>Ushma Mehta MS</b>, Senior Regulatory Expert, <i>MilliporeSigma</i></li> </ul> </td> </tr> <tr> <td data-bbox="236 1966 422 2089">11:45 – 12:05</td> <td data-bbox="422 1966 1535 2089"> <p><b>Continuous Virus Filtration Validation Strategies: Impact of ICH Q5A (R2)</b></p> <ul style="list-style-type: none"> <li>• <b>Julie Kozaili</b> , Principal Scientist, <i>Asahi Kasei</i></li> </ul> </td> </tr> </table>	11:05 – 11:25	<p><b>Continuous Biomanufacturing – ICH Q5A (R2) Training Materials</b></p> <ul style="list-style-type: none"> <li>• <b>Marie Murphy PhD</b>, , <i>Eli Lilly &amp; Co. Ireland</i></li> </ul>	11:25 – 11:45	<p><b>Viral Inactivation in Continuous Mode: Advancing Innovation Through Engagement With Regulatory Agencies</b></p> <ul style="list-style-type: none"> <li>• <b>Ushma Mehta MS</b>, Senior Regulatory Expert, <i>MilliporeSigma</i></li> </ul>	11:45 – 12:05	<p><b>Continuous Virus Filtration Validation Strategies: Impact of ICH Q5A (R2)</b></p> <ul style="list-style-type: none"> <li>• <b>Julie Kozaili</b> , Principal Scientist, <i>Asahi Kasei</i></li> </ul>		
11:05 – 11:25	<p><b>Continuous Biomanufacturing – ICH Q5A (R2) Training Materials</b></p> <ul style="list-style-type: none"> <li>• <b>Marie Murphy PhD</b>, , <i>Eli Lilly &amp; Co. Ireland</i></li> </ul>								
11:25 – 11:45	<p><b>Viral Inactivation in Continuous Mode: Advancing Innovation Through Engagement With Regulatory Agencies</b></p> <ul style="list-style-type: none"> <li>• <b>Ushma Mehta MS</b>, Senior Regulatory Expert, <i>MilliporeSigma</i></li> </ul>								
11:45 – 12:05	<p><b>Continuous Virus Filtration Validation Strategies: Impact of ICH Q5A (R2)</b></p> <ul style="list-style-type: none"> <li>• <b>Julie Kozaili</b> , Principal Scientist, <i>Asahi Kasei</i></li> </ul>								

12:05 – 13:00 **Open Discussion**

13:00 – 14:00 **Lunch Break**

**Viral Clearance**

**Moderator: David R. Van Houte PhD**, Senior Manager - QC Virology, *Regeneron Pharmaceuticals*

**Claiming Virus Reduction from Prior Knowledge**

14:00 – 14:20

- **Johannes Bluemel PhD**, Head of Virus Safety Section, *Paul-Ehrlich-Institut*

14:00 – 15:15

**TEM in Viral Safety: Bridging a Century of Virus Imaging with Modern Testing Standards**

14:20 – 14:40

- **Ashley Stephen Layland**, Project Director, *neotem Bioanalytics-IIT GmbH*

14:40 – 15:15 **Discussion Round**

15:15 – 15:45 **Coffee Break**

**Panel Discussion**

15:45 – 16:30

**Moderator: Simone Olgiati PhD**, Head of Molecular Biology Technology & Innovation, *Merck*

**Summary of the Workshop and Take-Home Messages**

16:30 – 16:50

**Alison Armstrong PhD**, *Merck KGaA*

16:50 – 17:00 **End of Workshop and Farewell**